Online citations, reference lists, and bibliographies.
← Back to Search

Zidovudine In Asymptomatic Human Immunodeficiency Virus Infection. A Controlled Trial In Persons With Fewer Than 500 CD4-positive Cells Per Cubic Millimeter. The AIDS Clinical Trials Group Of The National Institute Of Allergy And Infectious Diseases.

P. Volberding, S. Lagakos, M. Koch, C. Pettinelli, M. Myers, D. Booth, H. Balfour, R. Reichman, J. Bartlett, M. Hirsch
Published 1990 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus (HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a randomized, double-blind trial in adults with asymptomatic HIV infection who had CD4+ cell counts of fewer than 500 per cubic millimeter on entry into the study. The subjects (92 percent male) were randomly assigned to one of three treatment groups: placebo (428 subjects); zidovudine, 500 mg per day (453); or zidovudine, 1500 mg per day (457). After a mean follow-up of 55 weeks (range, 19 to 107), 33 of the subjects assigned to placebo had the acquired immunodeficiency syndrome (AIDS), as compared with 11 of those assigned to receive 500 mg of zidovudine (P = 0.002; relative risk, 2.8; 95 percent confidence interval, 1.4 to 5.6) and 14 of those assigned to receive 1500 mg of zidovudine (P = 0.05; relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.5). In the three treatment groups, the rates of progression (per 100 person-years) to either AIDS or advanced AIDS-related complex were 7.6, 3.6, and 4.3, respectively. As compared with those assigned to placebo, the subjects in the zidovudine groups had significant increases in the number of CD4+ cells and significant declines in p24 antigen levels. In the 1500-mg zidovudine group, severe hematologic toxicity (anemia or neutropenia) was more frequent than in the other groups (P less than 0.0001). In the 500-mg zidovudine group, nausea was the only toxicity that was significantly more frequent (in 3.3 percent) than in the placebo group (P = 0.001). We conclude that zidovudine is safe and effective in persons with asymptomatic HIV infection and fewer than 500 CD4+ cells per cubic millimeter. Additional study will be required to determine whether such treatment will ultimately improve survival for persons infected with HIV.
This paper references
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. Kaplan (1958)
Letter: Sterilisation of cardiac bioptome.
Maddocks Ac (1974)
10.1038/bjc.1977.1
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
10.2307/2530581
The Statistical Analysis of Failure Time Data.
M. Aitkin (1981)
10.7326/0003-4819-100-1-92
Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations
A. Fauci (1984)
10.2307/2987660
Clinical Trials: A Practical Approach
S. Pocock (1984)
10.1126/SCIENCE.6324345
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.
M. Sarngadharan (1984)
10.1073/PNAS.82.20.7096
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H. Mitsuya (1985)
10.7326/0003-4819-103-5-704
Immunopathogenesis of the Acquired Immunodeficiency Syndrome
D. Bowen (1985)
10.1093/BIOMET/72.2.359
Combining dependent tests with incomplete repeated measurements
Lee-Jen Wei (1985)
10.7326/0003-4819-105-2-234
Classification system for human T-lymphotropic virus type III/lymphadenopathy-associated virus infections.
D. S. Burke (1986)
10.1016/0090-1229(86)90135-2
Flow cytometric analysis of lymphocyte phenotypes in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence.
D. Stites (1986)
10.1056/NEJM198711193172101
Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City.
R. Rothenberg (1987)
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.1056/nejm198707233170402
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
D. Richman (1987)
10.1056/NEJM198707303170505
Pathogenesis of infection with human immunodeficiency virus.
D. Ho (1987)
10.1038/clpt.1987.49
Plasma and cerebrospinal fluid pharmacokinetics of 3′‐azido‐3′‐deoxythymidine: A Novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases
R. Klecker (1987)
10.7326/0003-4819-107-2-286
Detection of human immunodeficiency virus core protein in plasma by enzyme immunoassay. Association of antigenemia with symptomatic disease and T-helper cell depletion.
A. Wittek (1987)
Management of the neurologic complications of HIV infection and AIDS.
R. Price (1988)
10.1016/S0002-9343(88)80340-1
Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis.
P. Tellier (1988)
10.1056/NEJM198810063191401
Effect of Continuous Intravenous Infusion of Zidovudine (AZT) in Children with Symptomatic HIV Infection
P. Pizzo (1988)
10.1001/JAMA.1988.03410200065027
Survival experience among patients with AIDS receiving zidovudine. Follow-up of patients in a compassionate plea program.
T. Creagh-Kirk (1988)
10.1056/nejm198803173181113
Severe polymyositis-like syndrome associated with zidovudine therapy of AIDS and ARC.
L. Bessen (1988)
10.1016/S0140-6736(88)91865-X
NECROTISING MYOPATHY AND ZIDOVUDINE
D. Gorard (1988)
10.1093/INFDIS/157.5.1044
Survival patterns of the first 500 patients with AIDS in San Francisco.
P. Bacchetti (1988)
10.1136/BMJ.297.6656.1067
Predicting who will progress to AIDS.
A. Moss (1988)
10.7326/0003-4819-110-1-85
Zidovudine-induced hepatotoxicity.
G. Dubin (1989)
10.1126/SCIENCE.2467383
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
B. Larder (1989)



This paper is referenced by
10.1016/b978-0-12-819092-0.00029-7
AZT oxidative damage in the liver
A. Butanda-Ochoa (2021)
10.3366/soma.2020.0315
The Bio/Necropolitics of ACTG 076: Lessons from Pregnant Women of Colour Living with HIV for Treatment for Prevention in the Twenty-first Century
Eli Manning (2020)
10.1007/978-3-030-00054-7_13
Chagas Disease in Immunosuppressed Patients
A. Riarte (2019)
Risk Assessment System For Postoperative Concurrent Sepsis In HIV- Infected Trauma Patients
Baochi Liu (2019)
10.1007/s11481-019-09880-z
Evaluating Neurodevelopmental Consequences of Perinatal Exposure to Antiretroviral Drugs: Current Challenges and New Approaches
Jordan G. Schnoll (2019)
10.1017/S109285291800113X
Drug–drug interactions and clinical considerations with co-administration of antiretrovirals and psychotropic drugs
K. Goodlet (2018)
10.1111/bph.13798
Drug repurposing from the perspective of pharmaceutical companies
Y. Cha (2018)
10.1177/1740774518764449
How to construct an optimal interim report: What the data monitoring committee does and doesn’t need to know
J. Neaton (2018)
10.1007/164_2016_20
Translational Pharmacology in Glaucoma Neuroprotection.
L. Levin (2017)
10.1007/978-981-10-5178-4
Nutritional Anemia in Preschool Children
Prof. Anil Gupta (2017)
10.1007/978-981-10-5178-4_5
Aetiology of Iron Deficiency in Children
A. Gupta (2017)
10.1002/cyto.b.21400
Thirty‐five years of CD4 T‐cell counting in HIV infection: From flow cytometry in the lab to point‐of‐care testing in the field
L. Kestens (2017)
10.1093/biostatistics/kxw007
Efficient quantile marginal regression for longitudinal data with dropouts.
H. Cho (2016)
10.1021/ACS.ACCOUNTS.6B00274
Discovery and Development of the Anti-Human Immunodeficiency Virus Drug, Emtricitabine (Emtriva, FTC).
D. Liotta (2016)
10.22028/D291-26681
Improving and validating data-driven genotypic interpretation systems for the selection of antiretroviral therapies
A. Pironti (2016)
HIV: Treatment and Comorbidity
C. Rokx (2016)
10.1097/HRP.0000000000000120
Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity.
Adrienne T. Gerken (2016)
10.1093/jac/dkv429
Backbones versus core agents in initial ART regimens: one game, two players.
J. M. Llibre (2016)
10.1002/bimj.201400049
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.
M. Buyse (2016)
10.1016/B978-0-12-805302-7.00010-0
Chapter 10 – Contributions That Mitigated the Epidemic
D. Green (2016)
scanned from best copy available : may contain faint or blurred text , and / or cropped or missing
K. E. Wilson (2016)
How to Have Theory in an Epidemic: The Evolution of AIDS Treatment Activism
P. Treichler (2016)
10.1016/B978-0-12-805302-7.00004-5
The Human Immunodeficiency Virus
D. Green (2016)
10.1007/978-3-319-34004-3_2
A Historical Overview of the Epidemiology of HIV/AIDS in the United States
Jamal Jones (2016)
10.1016/B978-1-4557-4801-3.00124-7
General Clinical Manifestations of Human Immunodeficiency Virus Infection (Including Acute Retroviral Syndrome and Oral, Cutaneous, Renal, Ocular, Metabolic, and Cardiac Diseases)
Timothy R. Sterling (2015)
10.1080/15265161.2015.1010019
Not All RCTs Are Created Equal: Lessons From Early AIDS Trials
L. Dawson (2015)
10.1615/FORUMIMMUNDISTHER.2016014169
A Brief Chronicle of CD4 as a Biomarker for HIV/AIDS: A Tribute to the Memory of John L. Fahey.
J. Kagan (2015)
AIDS and the Social Sciences
Richard Ulack (2015)
10.14288/1.0166706
Tools and applications for DNA sequencing in the clinical management of viral infectious diseases : examples from HIV-1 and HCV
C. Brumme (2015)
10.1093/jac/dku516
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.
J. Moltó (2015)
10.1016/B978-0-7020-6285-8.00152-0
Drugs for HIV infection.
Benjamin Eckhardt (2014)
10.4172/JAA.10000111
Antiretroviral Toxicity Leading to a Medication Change in Multiple HIVClinics in Resource Limited Settings
Thomas Macharia (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar